Modern approaches to the management of patients with diabetic nephropathy

Background: Diabetic nephropathy (DN), a major complication of diabetes mellitus, is one of the leading causes of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide. The increasing global burden of diabetes, especially in low- and middle-income countries, has led to a parallel rise in diabetic kidney disease. This study reviews current evidence-based strategies for the diagnosis, prevention, and management of DN, highlighting recent advances in pharmacological therapies, biomarker discovery, and the integration of precision medicine. Methods and Materials: This project employed a comprehensive literature review using reputable databases including PubMed, Cochrane Library, Scopus, and guidelines from KDIGO and the American Diabetes Association. The methodology also involved synthesis of clinical trial data, expert consensus documents, and emerging research on novel therapeutic targets and biomarkers. Practical recommendations were developed through analysis and comparative evaluation of diagnostic and treatment algorithms. Results: Findings indicate that DN pathogenesis is multifactorial, involving hyperglycemia, oxidative stress, and dysregulated hemodynamics. Key diagnostic tools such as urine albumin-to-creatinine ratio (UACR), estimated glomerular filtration rate (eGFR), and emerging biomarkers (e.g., NGAL, KIM-1, and urinary nephrin) enhance early detection. Novel pharmacotherapies demonstrate renoprotective and cardioprotectiveincluding SGLT2 inhibitors, GLP-1 receptor agonists, and non-steroidal MRAs (e.g., finerenone). Lifestyle modifications and precision medicine approaches further optimize patient outcomes. Conclusion: The management of diabetic nephropathy requires a multidisciplinary, personalized, and evidence-based approach. Integration of early biomarkers, individualized glycemic and blood pressure control, RAAS inhibition, and new therapeutic agents can significantly delay disease progression and reduce cardiovascular risk. Future directions should emphasize precision medicine, continued research on novel agents, and collaborative care models to improve long-term outcomes in DN patients.